• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LRP6与结直肠癌和食管癌中Wnt/β-连环蛋白信号通路的关系

The Relationship between LRP6 and Wnt/β-Catenin Pathway in Colorectal and Esophageal Cancer.

作者信息

Shishido Akemi, Miyo Masaaki, Oishi Kazuki, Nishiyama Natsumi, Wu Meiqiao, Yamamoto Hiroyuki, Kouda Shihori, Wu Xin, Shibata Satoshi, Yokoyama Yuhki, Yamamoto Hirofumi

机构信息

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Yamadaoka 1-7, Suita City 565-0871, Japan.

Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita City 565-0871, Japan.

出版信息

Life (Basel). 2023 Feb 23;13(3):615. doi: 10.3390/life13030615.

DOI:10.3390/life13030615
PMID:36983771
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10057833/
Abstract

High expression of low-density lipoprotein receptor-related protein 6 (LRP6), a key component of the Wnt/β-catenin signaling pathway, is reported to be associated with malignant potential in some solid tumors including breast cancer and hepatocellular carcinoma. Few reports, however, have examined its function and clinical significance in colorectal cancers (CRC) demonstrating constitutive activation of Wnt signaling. Here, we compared the expression level and function of LRP6 in CRC with that of esophageal squamous cell carcinoma (ESCC) bearing few Wnt/β-catenin pathway mutations. On immunohistochemical staining, high LRP6 expression was noted in three of 68 cases (4.4%), and high β-catenin in 38 of 67 cases (56.7%) of CRC. High LRP6 expression was found in 21 of 82 cases (25.6%), and high β-catenin expression in 29 of 73 cases (39.7%) of ESCC. In our in vitro studies, LRP6 knockdown hardly changed Wnt signaling activity in CRC cell lines with mutations in Wnt signaling downstream genes. In contrast, in ESCC cell lines without Wnt signaling-related mutations, LRP6 knockdown significantly decreased Wnt signaling activity. LRP6 function may depend on constitutive activation of Wnt signaling.

摘要

低密度脂蛋白受体相关蛋白6(LRP6)是Wnt/β-连环蛋白信号通路的关键组成部分,据报道,其高表达与包括乳腺癌和肝细胞癌在内的一些实体瘤的恶性潜能相关。然而,很少有报道研究其在显示Wnt信号通路组成性激活的结直肠癌(CRC)中的功能和临床意义。在这里,我们比较了CRC中LRP6与几乎没有Wnt/β-连环蛋白通路突变的食管鳞状细胞癌(ESCC)中LRP6的表达水平和功能。免疫组织化学染色显示,68例CRC中有3例(4.4%)LRP6高表达,67例中有38例(56.7%)β-连环蛋白高表达。82例ESCC中有21例(25.6%)LRP6高表达,73例中有29例(39.7%)β-连环蛋白高表达。在我们的体外研究中,在Wnt信号下游基因突变的CRC细胞系中,LRP6敲低几乎不会改变Wnt信号活性。相反,在没有Wnt信号相关突变的ESCC细胞系中,LRP6敲低显著降低了Wnt信号活性。LRP6的功能可能依赖于Wnt信号的组成性激活。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5562/10057833/d057f70148dc/life-13-00615-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5562/10057833/d13940f81998/life-13-00615-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5562/10057833/74af198a4ee0/life-13-00615-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5562/10057833/20409cf634c4/life-13-00615-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5562/10057833/d057f70148dc/life-13-00615-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5562/10057833/d13940f81998/life-13-00615-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5562/10057833/74af198a4ee0/life-13-00615-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5562/10057833/20409cf634c4/life-13-00615-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5562/10057833/d057f70148dc/life-13-00615-g004.jpg

相似文献

1
The Relationship between LRP6 and Wnt/β-Catenin Pathway in Colorectal and Esophageal Cancer.LRP6与结直肠癌和食管癌中Wnt/β-连环蛋白信号通路的关系
Life (Basel). 2023 Feb 23;13(3):615. doi: 10.3390/life13030615.
2
Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.致癌性KRAS信号通过低密度脂蛋白受体相关蛋白6(LRP6)促进结直肠癌中的Wnt/β-连环蛋白信号通路。
Oncogene. 2015 Sep 17;34(38):4914-27. doi: 10.1038/onc.2014.416. Epub 2014 Dec 15.
3
VSTM2A suppresses colorectal cancer and antagonizes Wnt signaling receptor LRP6.VSTM2A 抑制结直肠癌并拮抗 Wnt 信号受体 LRP6。
Theranostics. 2019 Aug 21;9(22):6517-6531. doi: 10.7150/thno.34989. eCollection 2019.
4
A Role for the WNT Co-Receptor LRP6 in Pathogenesis and Therapy of Epithelial Cancers.WNT 共受体低密度脂蛋白受体相关蛋白 6(LRP6)在上皮性癌发生发展及治疗中的作用
Cancers (Basel). 2019 Aug 13;11(8):1162. doi: 10.3390/cancers11081162.
5
Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells.rottlerin诱导Wnt共受体LRP6降解,并抑制前列腺癌细胞和乳腺癌细胞中的Wnt/β-连环蛋白信号通路和mTORC1信号通路。
Cell Signal. 2014 Jun;26(6):1303-9. doi: 10.1016/j.cellsig.2014.02.018. Epub 2014 Mar 6.
6
CDDO-Me Elicits Anti-Breast Cancer Activity by Targeting LRP6 and FZD7 Receptor Complex.CDDO-Me 通过靶向 LRP6 和 FZD7 受体复合物发挥抗乳腺癌活性。
J Pharmacol Exp Ther. 2020 Apr;373(1):149-159. doi: 10.1124/jpet.119.263434. Epub 2020 Feb 3.
7
Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.水飞蓟宾通过抑制人前列腺和乳腺癌细胞中 Wnt 共受体 LRP6 的表达来抑制 Wnt/β-连环蛋白信号通路。
Cell Signal. 2012 Dec;24(12):2291-6. doi: 10.1016/j.cellsig.2012.07.009. Epub 2012 Jul 20.
8
Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion.LRP6 是 Wnt 共受体,其表达上调促进肝癌发生,并增强细胞侵袭。
PLoS One. 2012;7(5):e36565. doi: 10.1371/journal.pone.0036565. Epub 2012 May 3.
9
LRP6 mediates Wnt/β-catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells.LRP6 介导 Wnt/β-连环蛋白信号通路并调节人骨髓间充质干细胞的成脂分化。
Int J Biochem Cell Biol. 2012 Nov;44(11):1970-82. doi: 10.1016/j.biocel.2012.07.025. Epub 2012 Aug 2.
10
Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells.巨肌醇抑制 Wnt/β-连环蛋白信号通路并在乳腺癌细胞中发挥抗癌活性。
BMC Complement Altern Med. 2018 Feb 14;18(1):59. doi: 10.1186/s12906-018-2108-x.

引用本文的文献

1
Targeting PAR-2-driven inflammatory pathways in colorectal cancer: mechanistic insights from atorvastatin and rosuvastatin treatment in cell line models.靶向结直肠癌中PAR-2驱动的炎症通路:阿托伐他汀和瑞舒伐他汀在细胞系模型治疗中的机制见解
Transl Cancer Res. 2025 Mar 30;14(3):1531-1566. doi: 10.21037/tcr-24-1027. Epub 2025 Mar 27.
2
Evaluation of LRP6, SFRP3, and DVL1 Protein Concentrations in Serum of Patients with Gastroenteropancreatic or Bronchopulmonary Neuroendocrine Tumors.胃肠胰或支气管肺神经内分泌肿瘤患者血清中LRP6、SFRP3和DVL1蛋白浓度的评估
Cancers (Basel). 2024 Dec 27;17(1):47. doi: 10.3390/cancers17010047.
3

本文引用的文献

1
Improved In Vivo Delivery of Small RNA Based on the Calcium Phosphate Method.基于磷酸钙法的小RNA体内递送效果的改善
J Pers Med. 2021 Nov 8;11(11):1160. doi: 10.3390/jpm11111160.
2
Roles of G Protein-Coupled Receptors (GPCRs) in Gastrointestinal Cancers: Focus on Sphingosine 1-Shosphate Receptors, Angiotensin II Receptors, and Estrogen-Related GPCRs.G 蛋白偶联受体(GPCRs)在胃肠道癌症中的作用:聚焦于鞘氨醇 1-磷酸受体、血管紧张素 II 受体和雌激素相关 GPCRs。
Cells. 2021 Nov 3;10(11):2988. doi: 10.3390/cells10112988.
3
LRP6 as a biomarker of poor prognosis of breast cancer.
The Complex Connection Between Myocardial Dysfunction and Cancer Beyond Cardiotoxicity: Shared Risk Factors and Common Molecular Pathways.
心肌功能障碍与癌症之间的复杂联系:超越心脏毒性的关联——共同风险因素和常见分子途径
Int J Mol Sci. 2024 Dec 8;25(23):13185. doi: 10.3390/ijms252313185.
4
Wnt signalosomes: What we know that we do not know.Wnt信号小体:我们已知我们未知之事。
Bioessays. 2025 Feb;47(2):e2400110. doi: 10.1002/bies.202400110. Epub 2024 Nov 9.
LRP6作为乳腺癌预后不良的生物标志物。
Gland Surg. 2021 Aug;10(8):2414-2427. doi: 10.21037/gs-21-194.
4
The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy.Wnt信号通路在肿瘤发生、药理学靶点及癌症治疗药物研发中的作用
Biomark Res. 2021 Sep 6;9(1):68. doi: 10.1186/s40364-021-00323-7.
5
Wnt/β-catenin signaling in cancers and targeted therapies.Wnt/β-连环蛋白信号通路在癌症和靶向治疗中的作用。
Signal Transduct Target Ther. 2021 Aug 30;6(1):307. doi: 10.1038/s41392-021-00701-5.
6
Unveiling the Roles of Low-Density Lipoprotein Receptor-Related Protein 6 in Intestinal Homeostasis, Regeneration and Oncogenesis.揭示低密度脂蛋白受体相关蛋白 6 在肠道稳态、再生和肿瘤发生中的作用。
Cells. 2021 Jul 15;10(7):1792. doi: 10.3390/cells10071792.
7
The Limitless Future of RNA Therapeutics.RNA疗法的无限未来。
Front Bioeng Biotechnol. 2021 Mar 18;9:628137. doi: 10.3389/fbioe.2021.628137. eCollection 2021.
8
Mutations and mechanisms of WNT pathway tumour suppressors in cancer.癌症中 WNT 通路肿瘤抑制因子的突变和机制。
Nat Rev Cancer. 2021 Jan;21(1):5-21. doi: 10.1038/s41568-020-00307-z. Epub 2020 Oct 23.
9
MicroRNA‑590 inhibits migration, invasion and epithelial‑to‑mesenchymal transition of esophageal squamous cell carcinoma by targeting low‑density lipoprotein receptor‑related protein 6.微小 RNA-590 通过靶向低密度脂蛋白受体相关蛋白 6 抑制食管鳞癌细胞的迁移、侵袭和上皮-间充质转化。
Oncol Rep. 2020 Oct;44(4):1385-1392. doi: 10.3892/or.2020.7692. Epub 2020 Jul 15.
10
Regulation of Wnt Signaling through Ubiquitination and Deubiquitination in Cancers.Wnt 信号通路在癌症中的泛素化和去泛素化调控。
Int J Mol Sci. 2020 May 30;21(11):3904. doi: 10.3390/ijms21113904.